Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00083489" target="_blank" >RIV/00216224:14110/15:00083489 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/15:00063165

Výsledek na webu

<a href="http://www.ajconline.org/article/S0002-9149(15)01346-6/abstract" target="_blank" >http://www.ajconline.org/article/S0002-9149(15)01346-6/abstract</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.amjcard.2015.05.022" target="_blank" >10.1016/j.amjcard.2015.05.022</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy

Popis výsledku v původním jazyce

The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment- phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by thepatient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 +/- 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the useof PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy.

Název v anglickém jazyce

Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy

Popis výsledku anglicky

The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment- phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by thepatient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 +/- 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the useof PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.100%2F02%2F0123" target="_blank" >ED1.100/02/0123: Fakultní nemocnice u sv. Anny v Brně - Mezinárodní centrum klinického výzkumu (FNUSA - ICRC)</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American Journal of Cardiology

ISSN

0002-9149

e-ISSN

—

Svazek periodika

116

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

618-621

Kód UT WoS článku

000360253800020

EID výsledku v databázi Scopus

—